| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10040202 | HBV | ENSG00000157404.17 | protein_coding | KIT | Yes | No | 3815 | P10721 |
| TVIS10040086 | HBV | ENSG00000157404.17 | protein_coding | KIT | Yes | No | 3815 | P10721 |
| TVIS30010849 | HIV | ENSG00000157404.17 | protein_coding | KIT | Yes | No | 3815 | P10721 |
| TVIS20037373 | HPV | ENSG00000157404.17 | protein_coding | KIT | Yes | No | 3815 | P10721 |
| TVIS20039601 | HPV | ENSG00000157404.17 | protein_coding | KIT | Yes | No | 3815 | P10721 |
| TVIS44012431 | HTLV-1 | ENSG00000157404.17 | protein_coding | KIT | Yes | No | 3815 | P10721 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | KIT |
|---|---|
| DrugBank ID | DB00619 |
| Drug Name | Imatinib |
| Target ID | BE0000453 |
| UniProt ID | P10721 |
| Regulation Type | antagonist |
| PubMed IDs | 16865565; 16087693; 17458563; 17369583; 17559139 |
| Citations | Lee JL, Kim JY, Ryu MH, Kang HJ, Chang HM, Kim TW, Lee H, Park JH, Kim HC, Kim JS, Kang YK: Response to imatinib in KIT- and PDGFRA-wild type gastrointestinal stromal associated with neurofibromatosis type 1. Dig Dis Sci. 2006 Jun;51(6):1043-6.@@Dy GK, Miller AA, Mandrekar SJ, Aubry MC, Langdon RM Jr, Morton RF, Schild SE, Jett JR, Adjei AA: A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol. 2005 Nov;16(11):1811-6. Epub 2005 Aug 8.@@Rutkowski P, Nowecki ZI, Debiec-Rychter M, Grzesiakowska U, Michej W, Wozniak A, Siedlecki JA, Limon J, vel Dobosz AJ, Kakol M, Osuch C, Ruka W: Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs). J Cancer Res Clin Oncol. 2007 Sep;133(9):589-97. Epub 2007 Apr 26.@@De Giorgi U: KIT mutations and imatinib dose effects in patients with gastrointestinal stromal tumors. J Clin Oncol. 2007 Mar 20;25(9):1146-7; author reply 1147-8.@@Posadas EM, Kwitkowski V, Kotz HL, Espina V, Minasian L, Tchabo N, Premkumar A, Hussain MM, Chang R, Steinberg SM, Kohn EC: A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling. Cancer. 2007 Jul 15;110(2):309-17. |
| Groups | Approved |
| Direct Classification | Benzanilides |
| SMILES | CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1 |
| Pathways | Imatinib Inhibition of BCR-ABL |
| PharmGKB | PA10804 |
| ChEMBL | CHEMBL941 |
